MRI as a window into bone marrow disease: a new biomarker test?

NCT ID NCT01973881

Recruiting now Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study explores whether MRI scans can serve as biomarkers for myelofibrosis, a bone marrow disorder. Researchers will measure water diffusion and fat content in the bone marrow using MRI before, during, and after treatment. The goal is to see if these imaging parameters can determine the extent of disease and predict how well a patient responds to therapy. Adults with myelofibrosis who can safely undergo MRI are eligible to participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnetic resonance imaging (MRI) scans
What this could lead to: If successful, MRI could become a non-invasive way to gauge myelofibrosis severity and detect treatment response earlier than current methods.
What could go wrong: This is a pilot study, so the MRI parameters may not prove reliable as biomarkers. Results may not generalize to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS

Contacts and locations

Locations

University of Michigan Hospital
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.